DK1680134T4 - Sammensætninger og anvendelser deraf - Google Patents
Sammensætninger og anvendelser deraf Download PDFInfo
- Publication number
- DK1680134T4 DK1680134T4 DK04798407.5T DK04798407T DK1680134T4 DK 1680134 T4 DK1680134 T4 DK 1680134T4 DK 04798407 T DK04798407 T DK 04798407T DK 1680134 T4 DK1680134 T4 DK 1680134T4
- Authority
- DK
- Denmark
- Prior art keywords
- starch
- glucose
- starches
- native
- crystalline
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 229920002472 Starch Polymers 0.000 claims abstract description 150
- 235000019698 starch Nutrition 0.000 claims abstract description 147
- 239000008107 starch Substances 0.000 claims abstract description 106
- 235000013305 food Nutrition 0.000 claims abstract description 33
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 21
- 208000007345 glycogen storage disease Diseases 0.000 claims abstract description 19
- 208000013016 Hypoglycemia Diseases 0.000 claims abstract description 16
- 208000019423 liver disease Diseases 0.000 claims abstract description 3
- 229920002261 Corn starch Polymers 0.000 claims description 42
- 238000011282 treatment Methods 0.000 claims description 24
- 229920000945 Amylopectin Polymers 0.000 claims description 14
- 239000008120 corn starch Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000002218 hypoglycaemic effect Effects 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 91
- 239000008103 glucose Substances 0.000 abstract description 88
- 238000000034 method Methods 0.000 abstract description 19
- 210000002966 serum Anatomy 0.000 abstract description 7
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- 235000014268 sports nutrition Nutrition 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 34
- 239000008280 blood Substances 0.000 description 34
- 235000019759 Maize starch Nutrition 0.000 description 33
- 230000007062 hydrolysis Effects 0.000 description 19
- 238000006460 hydrolysis reaction Methods 0.000 description 19
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 18
- 150000002632 lipids Chemical class 0.000 description 18
- 240000008042 Zea mays Species 0.000 description 16
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 16
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 16
- 235000009973 maize Nutrition 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 230000029087 digestion Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 229920000856 Amylose Polymers 0.000 description 11
- 229920002527 Glycogen Polymers 0.000 description 11
- 229940096919 glycogen Drugs 0.000 description 11
- 229920002774 Maltodextrin Polymers 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 9
- 102000013142 Amylases Human genes 0.000 description 6
- 108010065511 Amylases Proteins 0.000 description 6
- 235000019418 amylase Nutrition 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 230000030136 gastric emptying Effects 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 150000004804 polysaccharides Chemical class 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000004382 Amylase Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000209140 Triticum Species 0.000 description 5
- 235000021307 Triticum Nutrition 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940099112 cornstarch Drugs 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 235000010987 pectin Nutrition 0.000 description 5
- 239000001814 pectin Substances 0.000 description 5
- 229920001277 pectin Polymers 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 235000020161 semi-skimmed milk Nutrition 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- 229920000310 Alpha glucan Polymers 0.000 description 4
- 229920001685 Amylomaize Polymers 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 229940072056 alginate Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 235000019621 digestibility Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 102000009097 Phosphorylases Human genes 0.000 description 3
- 108010073135 Phosphorylases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 229940100486 rice starch Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 229920000294 Resistant starch Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 235000015897 energy drink Nutrition 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000021254 resistant starch Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 102000003925 1,4-alpha-Glucan Branching Enzyme Human genes 0.000 description 1
- 108090000344 1,4-alpha-Glucan Branching Enzyme Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 208000029448 Chylomicron retention disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 208000006562 Glycogen Storage Disease Type VII Diseases 0.000 description 1
- 208000032003 Glycogen storage disease due to glucose-6-phosphatase deficiency Diseases 0.000 description 1
- 206010018464 Glycogen storage disease type I Diseases 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 206010053250 Glycogen storage disease type III Diseases 0.000 description 1
- 206010018462 Glycogen storage disease type V Diseases 0.000 description 1
- 206010053240 Glycogen storage disease type VI Diseases 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 230000004099 anaerobic respiration Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000008984 colonic lesion Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 201000004541 glycogen storage disease I Diseases 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 201000004534 glycogen storage disease V Diseases 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000009561 snack bars Nutrition 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 235000012794 white bread Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (6)
1. Anvendelse af stivelse i fremstillingen af en terapeutisk levnedsmiddelsammensætning eller en terapeutisk fødevare til behandling eller forebyggelse af hypoglykæmi hos et individ, hvor stivelsen er semikrystallinsk varme-fugt-behandlet voksmajsstivelse.
2. Anvendelse ifølge krav 1, hvor individet har glykogenose.
3. Anvendelse ifølge krav 1, hvor individet har type I eller type II diabetes.
4. Anvendelse ifølge krav 1, hvor individet har leversygdom forbundet med tilstedeværelsen eller risikoen for hypoglykæmi.
5. Anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor den varme-fugtbehandlede fødevarestivelse er en semikrystallinsk stivelse og den semikrystallinske stivelse har et amylopectin-indhold på mindst 70 %.
6. Anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor den semikrystallinske stivelse har et amylopectin-indhold på mindst 80 %.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0325942.1A GB0325942D0 (en) | 2003-11-06 | 2003-11-06 | Compositions and uses thereof |
PCT/GB2004/004682 WO2005044284A1 (en) | 2003-11-06 | 2004-11-08 | Compositions and uses therof |
Publications (2)
Publication Number | Publication Date |
---|---|
DK1680134T3 DK1680134T3 (da) | 2014-07-14 |
DK1680134T4 true DK1680134T4 (da) | 2018-04-23 |
Family
ID=29726075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04798407.5T DK1680134T4 (da) | 2003-11-06 | 2004-11-08 | Sammensætninger og anvendelser deraf |
Country Status (17)
Country | Link |
---|---|
US (1) | US8507462B2 (da) |
EP (1) | EP1680134B2 (da) |
JP (1) | JP5248776B2 (da) |
CN (1) | CN1901922B (da) |
AU (1) | AU2004287263B2 (da) |
CA (1) | CA2544965C (da) |
CY (1) | CY1115306T1 (da) |
DK (1) | DK1680134T4 (da) |
ES (1) | ES2478565T5 (da) |
GB (1) | GB0325942D0 (da) |
HK (1) | HK1097754A1 (da) |
HR (1) | HRP20140660T4 (da) |
NZ (1) | NZ546987A (da) |
PL (1) | PL1680134T5 (da) |
PT (1) | PT1680134E (da) |
SI (1) | SI1680134T2 (da) |
WO (1) | WO2005044284A1 (da) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0325942D0 (en) † | 2003-11-06 | 2003-12-10 | Glycologic Ltd | Compositions and uses thereof |
US8557274B2 (en) | 2005-12-06 | 2013-10-15 | Purdue Research Foundation | Slowly digesting starch and fermentable fiber |
WO2010077635A2 (en) * | 2008-12-09 | 2010-07-08 | The Ucan Company | Heat moisture treated carbohydrates and uses thereof |
US9481777B2 (en) | 2012-03-30 | 2016-11-01 | The Procter & Gamble Company | Method of dewatering in a continuous high internal phase emulsion foam forming process |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1306384A (da) * | 1969-05-05 | 1973-02-07 | ||
GB2026837A (en) * | 1978-07-31 | 1980-02-13 | Cpc International Inc | Starch containing food products |
WO1990015147A1 (en) † | 1989-06-06 | 1990-12-13 | Washington State University Research Foundation, Inc. | Purified resistant starch products and their preparation |
JP2996707B2 (ja) * | 1990-09-21 | 2000-01-11 | 三和興産株式会社 | 湿熱処理澱粉の効率的製造法 |
JPH06169680A (ja) * | 1992-12-09 | 1994-06-21 | Sanwa Kosan Kk | パン類およびパン粉の製造法 |
IL112967A0 (en) † | 1994-03-15 | 1995-06-29 | Los Angeles Childrens Hospital | Pharmaceutical compositions comprising a complex carbohydrate to diminish hypoglycemia in patients with diabetes mellitus |
US5843921A (en) † | 1994-03-15 | 1998-12-01 | Childrens Hospital Of Los Angeles | Therapeutic food composition and method to diminish blood sugar fluctuations |
US5605893A (en) * | 1994-03-15 | 1997-02-25 | Children's Hospital Of Los Angeles | Method of using a therapeutic food composition to diminish blood sugar fluctuations in diabetic patients |
US5576048A (en) * | 1995-06-07 | 1996-11-19 | American Maize-Products Company | Foodstuffs containing a waxy waxy amylose extender starch |
JP2790610B2 (ja) * | 1994-07-21 | 1998-08-27 | ホクレン農業協同組合連合会 | α−グルコシダーゼ阻害剤、それを含む糖組成物、甘味料、食品、及び飼料 |
JPH09172961A (ja) * | 1995-12-22 | 1997-07-08 | Oyama Nyugyo Nogyo Kyodo Kumiai | ファットスプレッド様の発酵乳 |
JPH11130696A (ja) * | 1997-08-27 | 1999-05-18 | Takeda Chem Ind Ltd | 経口徐放性製剤 |
US6238708B1 (en) * | 1999-02-23 | 2001-05-29 | The Iams Company | Composition and process for controlling glucose metabolism in companion animals by dietary starch |
DE19911001C2 (de) * | 1999-03-12 | 2002-06-20 | Aventis Cropscience Gmbh | Verfahren zur Herstellung resistenter Stärke, resistente Stärke und deren Verwendung |
FR2791686A1 (fr) * | 1999-03-30 | 2000-10-06 | Ulice | Produits issus d'un ble a tres haute teneur en amylopectine et ses applications. |
US6733815B2 (en) * | 1999-04-16 | 2004-05-11 | Cargill, Incorporated | Food ingredient containing wheat gluten, soy grits and soy flour |
JP3113873B1 (ja) * | 1999-11-09 | 2000-12-04 | 株式会社日麺 | ゆで麺及びその製造法 |
AUPQ673300A0 (en) * | 2000-04-06 | 2000-05-04 | Penford Australia Limited | Starch sub-types and lipid metabolism |
JP2004512306A (ja) * | 2000-10-25 | 2004-04-22 | メットコン・メディシン・アクチボラゲット | 血糖代謝異常の処置のための新規組成物および方法 |
US6890571B2 (en) † | 2002-05-14 | 2005-05-10 | National Starch And Chemical Investment Holding Corporation | Slowly digestible starch product |
US7081261B2 (en) † | 2002-05-14 | 2006-07-25 | National Starch And Chemical Investment Holding Corporation | Resistant starch prepared by isoamylase debranching of low amylose starch |
GB0325942D0 (en) † | 2003-11-06 | 2003-12-10 | Glycologic Ltd | Compositions and uses thereof |
US20060025381A1 (en) † | 2004-07-29 | 2006-02-02 | National Starch And Chemical Investment Holding Company | Use of a chemically modified starch product |
-
2003
- 2003-11-06 GB GBGB0325942.1A patent/GB0325942D0/en not_active Ceased
-
2004
- 2004-11-08 AU AU2004287263A patent/AU2004287263B2/en not_active Expired
- 2004-11-08 CN CN2004800399980A patent/CN1901922B/zh not_active Expired - Lifetime
- 2004-11-08 CA CA2544965A patent/CA2544965C/en not_active Expired - Lifetime
- 2004-11-08 ES ES04798407.5T patent/ES2478565T5/es not_active Expired - Lifetime
- 2004-11-08 WO PCT/GB2004/004682 patent/WO2005044284A1/en active Application Filing
- 2004-11-08 US US10/578,551 patent/US8507462B2/en active Active
- 2004-11-08 NZ NZ546987A patent/NZ546987A/en not_active IP Right Cessation
- 2004-11-08 EP EP04798407.5A patent/EP1680134B2/en not_active Expired - Lifetime
- 2004-11-08 JP JP2006538929A patent/JP5248776B2/ja not_active Expired - Lifetime
- 2004-11-08 DK DK04798407.5T patent/DK1680134T4/da active
- 2004-11-08 PL PL04798407T patent/PL1680134T5/pl unknown
- 2004-11-08 SI SI200432172T patent/SI1680134T2/en unknown
- 2004-11-08 PT PT47984075T patent/PT1680134E/pt unknown
-
2007
- 2007-04-19 HK HK07104115.5A patent/HK1097754A1/xx not_active IP Right Cessation
-
2014
- 2014-07-07 CY CY20141100507T patent/CY1115306T1/el unknown
- 2014-07-11 HR HRP20140660TT patent/HRP20140660T4/hr unknown
Also Published As
Publication number | Publication date |
---|---|
PL1680134T3 (pl) | 2014-10-31 |
CN1901922A (zh) | 2007-01-24 |
SI1680134T2 (en) | 2018-04-30 |
ES2478565T3 (es) | 2014-07-22 |
EP1680134B2 (en) | 2018-03-07 |
NZ546987A (en) | 2009-09-25 |
JP5248776B2 (ja) | 2013-07-31 |
EP1680134B1 (en) | 2014-04-30 |
HRP20140660T1 (en) | 2014-10-10 |
WO2005044284A1 (en) | 2005-05-19 |
PT1680134E (pt) | 2014-07-16 |
GB0325942D0 (en) | 2003-12-10 |
US20070077277A1 (en) | 2007-04-05 |
EP1680134A1 (en) | 2006-07-19 |
CA2544965A1 (en) | 2005-05-19 |
ES2478565T5 (es) | 2018-04-17 |
JP2007510704A (ja) | 2007-04-26 |
PL1680134T5 (pl) | 2018-06-29 |
HK1097754A1 (en) | 2007-07-06 |
HRP20140660T4 (hr) | 2018-08-10 |
AU2004287263A1 (en) | 2005-05-19 |
CN1901922B (zh) | 2011-10-26 |
CY1115306T1 (el) | 2017-01-04 |
US8507462B2 (en) | 2013-08-13 |
DK1680134T3 (da) | 2014-07-14 |
CA2544965C (en) | 2013-10-29 |
AU2004287263B2 (en) | 2011-01-27 |
SI1680134T1 (sl) | 2014-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004161998A (ja) | 可溶性の高度に分枝したグルコースポリマーおよびその製造方法 | |
TWI308490B (en) | Use of pullulan as a slowly digested carbohydrate | |
AU2006340298B2 (en) | Gastric raft composition comprising preferably processed starches for inducing satiety | |
EP2308320B1 (en) | Hydroxypropylated starch for preventing/treating diabetes | |
Valencia et al. | Artificial rice as an alternative functional food to support food diversification program | |
DK1680134T4 (da) | Sammensætninger og anvendelser deraf | |
JP2911048B2 (ja) | 食物繊維含有澱粉加工食品及びその製造法 | |
EP1787625B1 (en) | Preventive/remedy for obesity | |
CA2578958C (en) | Acetylated starch or starch succinate for treatment of obesity or diabetes | |
JP4463494B2 (ja) | 便秘改善剤 | |
EP1545563B1 (en) | Composition and method for use in intestinal cleansing procedures | |
JP2000032951A (ja) | 水分、食品および医薬品等の嚥下並びに服用補助のための粘稠化組成物 |